Literature DB >> 16330448

The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.

Carlos María Galmarini, Emeline Cros, Xavier Thomas, Lars Jordheim, Charles Dumontet.   

Abstract

We analyzed the expression of deoxycytidine kinase (dCK), UMP/CMP-kinase (UMP/CMP-K), nucleotide diphosphokinase (NDPK-B) and 5'-nucleotidases cN-II, cN-III, cdN and mdN by quantitative polymerase chain reaction at diagnosis in leukemic blasts from 96 patients with acute myeloid leukemia (AML) treated with ara-C. Our results show that high mRNA levels of cN-II and low mRNA levels of cN-III are correlated with a worse clinical outcome and suggest that these enzymes may have a role in sensitivity to ara-C in AML patients.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16330448

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  14 in total

Review 1.  Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity.

Authors:  Christine M Hartford; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2007-09       Impact factor: 2.533

2.  Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

Authors:  Amit K Mitra; Kristine R Crews; Stanley Pounds; Xueyuan Cao; Tanya Feldberg; Yogita Ghodke; Varsha Gandhi; William Plunkett; M Eileen Dolan; Christine Hartford; Susana Raimondi; Dario Campana; James Downing; Jeffrey E Rubnitz; Raul C Ribeiro; Jatinder K Lamba
Journal:  J Pharmacol Exp Ther       Date:  2011-06-28       Impact factor: 4.030

Review 3.  MOB control: reviewing a conserved family of kinase regulators.

Authors:  Alexander Hergovich
Journal:  Cell Signal       Date:  2011-04-21       Impact factor: 4.315

4.  Identification of a new translocation that disrupts the RUNX1 gene in a patient with de novo acute myeloid leukemia.

Authors:  Antonio Roberto Lucena-Araujo; Lorena Lobo de Figueiredo-Pontes; Fábio Morato de Oliveira; Maria de Lourdes Chauffaille; Roberto Passetto Falcao; Eduardo Magalhães Rego
Journal:  Med Oncol       Date:  2011-03-06       Impact factor: 3.064

Review 5.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

Review 6.  The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.

Authors:  Ashkan Emadi; Judith E Karp
Journal:  Pharmacogenomics       Date:  2012-08       Impact factor: 2.533

7.  Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.

Authors:  Liang Li; Brooke Fridley; Krishna Kalari; Gregory Jenkins; Anthony Batzler; Stephanie Safgren; Michelle Hildebrandt; Matthew Ames; Daniel Schaid; Liewei Wang
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

8.  SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.

Authors:  Haixia Wan; Jianyi Zhu; Fangyuan Chen; Fei Xiao; Honghui Huang; Xiaofeng Han; Lu Zhong; Hua Zhong; Lan Xu; Beiwen Ni; Jihua Zhong
Journal:  J Exp Clin Cancer Res       Date:  2014-11-15

9.  RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.

Authors:  Ajay Abraham; Savitha Varatharajan; Sreeja Karathedath; Chepsy Philip; Kavitha M Lakshmi; Ashok Kumar Jayavelu; Ezhilpavai Mohanan; Nancy Beryl Janet; Vivi M Srivastava; Ramachandran V Shaji; Wei Zhang; Aby Abraham; Auro Viswabandya; Biju George; Mammen Chandy; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Pharmacogenomics       Date:  2015-06-17       Impact factor: 2.533

10.  Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts.

Authors:  Zheng Shen; John V Fahey; Jack E Bodwell; Marta Rodriguez-Garcia; Richard M Rossoll; Sarah G Crist; Mickey V Patel; Charles R Wira
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.